Gut Microbes, Risperidone, and a New Therapeutic Path

In this episode of The APS Publications Podcast, coauthors Matthew A. Hadiono, Alexis B. Kazen, Fatima A. Aboulalazm, and John R. Kirby discuss their recent study, "Reutericyclin mitigates risperidone-induced suppression of anaerobic energy expenditure," published in AJP–Regulatory, Integrative and Comparative Physiology.

The authors explore how the gut microbiome, a thermogenic biomass, plays a critical role in regulating energy expenditure. Their study shows that the composition of the microbial community, influenced by both xenobiotics and bacterial metabolites, can impact metabolic function. They found that treatment with reutericyclin counteracts the suppression of anaerobic energy expenditure caused by risperidone. These findings suggest that reutericyclin may offer a new therapeutic approach for managing obesity.

Tune in to learn more about the gut microbiome’s role in energy balance and the potential for microbiota-targeted therapies.

 

Reutericyclin mitigates risperidone-induced suppression of anaerobic energy expenditure

Matthew A. Hadiono, Alexis B. Kazen, Fatima A. Aboulalazm, Colin M. L. Burnett, John J. Reho, Tammy L. Kindel, Justin L. Grobe, and John R. Kirby

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2025 328:6, R741-R757